Evidence map›Paper›PMID 29903418›Full record

ArticleTrends in microbiology2018

Directly Bactericidal Anti-Escherichia coli Antibody.

Valéria Szijártó, Eszter Nagy, Gábor Nagy

Abstract readComment
PubMed Publisher
In one paragraph

Article in Trends in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Valéria SzijártóArsanis Biosciences, Vienna, Austria; Presently independent researchers, Vienna, Austria. Electronic address: valeria.szijarto@gmail.com.
Eszter NagyArsanis Biosciences, Vienna, Austria; Presently independent researchers, Vienna, Austria.
Gábor NagyArsanis Biosciences, Vienna, Austria; Presently independent researchers, Vienna, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal antibodies are considered promising therapeutic alternatives to fight antibiotic-resistant bacteria. Upon binding to their targets, they either act alone (e.g., by neutralizing bacterial toxins) or in concert with the host's immune system (with complement or phagocytes). Storek et al. have described a unique, directly bactericidal antibody against Escherichia coli.

Indexed as

Antibodies, BacterialAnti-Bacterial AgentsAntibodies, MonoclonalComplement System ProteinsEscherichia coliAnti-Bacterial AgentsAntibodies, BacterialAntibodies, MonoclonalComplement System Proteinsbactericidal activityEscherichia colimonoclonal antibody

Identifiers

PMID29903418

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.